Jürgen Bickel is not only the founder and managing director of Storz & Bickel, he’s also a longtime client of the company’s iconic cannabis smoking device.

The medically certified product manufacturer, based in Tuttlingen, Germany, is celebrating the 25th anniversary of its Volcano vaporizer, which has sold hundreds of thousands of units worldwide since its early days on the market when Bickel first tried it as a consumer.

ADVERTISEMENT

“It’s really for people who are frequently using cannabis,” he told MJBizDaily during a recent interview and product demo at a private cabana at The Woods in West Hollywood, California.

“There’s a lot of patients who really need to use it several times a day.

“They need reliability and reproducibility.”

The Woods, owned by

Read full article on Marijuana Business Daily

Virginia appears set to remain the only state in the country with recreational marijuana legalization but without legal sales.

That status quo would continue if, as widely expected, Republican Gov. Glenn Youngkin again vetoes adult-use sales legalization bills that state lawmakers recently sent to him.

ADVERTISEMENT

For the second straight year, Virginia’s Democratic-controlled General Assembly passed legislation that would finally set up adult-use sales in the state.

Youngkin’s Democratic predecessor, Ralph Northam, signed legalization into law in 2021, but that bill had a clause that required further action to create a market projected to be worth hundreds of millions.

The most recent legislation would give exclusive adult-use sales rights to the state’s existing medical marijuana businesses, which include major multistate operators such as:

Read full article on Marijuana Business Daily

The Trump administration’s plan to cut federal research funding threatens 565 ongoing experiments involving cannabis, according to an MJBizDaily review and interviews with scientists and academics.

An accompanying freeze of new National Institutes of Health (NIH) grants is also stymieing future research at a key moment – and raising questions about the fate of marijuana rescheduling as well as suggesting profound consequences for the regulated MJ industry.

ADVERTISEMENT

The NIH announced Feb. 7 that it would drastically reduce to no more than 15% the amount of “indirect costs” – money used to cover administrative and facility-related bills – financed by federal research grants.

Without fully funded indirect costs, “I literally cannot do my research,” Angela Bryan, a professor of psychology and neuroscience at the

Read full article on Marijuana Business Daily